Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Salzgitter Hold (DPA-AFX) +++ SALZGITTER Aktie -3,78%

OCUGEN Aktie

 >OCUGEN Aktienkurs 
0.8998 EUR    +0.9%    (Tradegate)
Ask: 0.8998 EUR / 1888 Stück
Bid: 0.8722 EUR / 2800 Stück
Tagesumsatz: 21061 Stück
Realtime Kurs von 8 bis 22 Uhr!
OCUGEN Aktie über LYNX handeln
>OCUGEN Performance
1 Woche: +11,8%
1 Monat: -3,7%
3 Monate: +62,7%
6 Monate: +9,0%
1 Jahr: -44,7%
laufendes Jahr: +3,6%
>OCUGEN Aktie
Name:  OCUGEN INC. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US67577C1053 / A2PSZH
Symbol/ Ticker:  2H51 (Frankfurt) / OCGN (NASDAQ)
Kürzel:  FRA:2H51, ETR:2H51, 2H51:GR, NASDAQ:OCGN
Index:  -
Webseite:  https://ocugen.com/
Marktkapitalisierung:  304.51 Mio. EUR
Umsatz:  3.92 Mio. EUR
EBITDA:  -47.11 Mio. EUR
Gewinn je Aktie:  -0.147 EUR
Schulden:  27.59 Mio. EUR
Liquide Mittel:  32.77 Mio. EUR
Umsatz-/ Gewinnwachstum:  46.1% / -
KGV/ KGV lG:  2.31 / -
KUV/ KBV/ PEG:  73.88 / 21.92 / -
Gewinnm./ Eigenkapitalr.:  - / -248.97%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  OCUGEN
Letzte Datenerhebung:  09.07.25
>OCUGEN Eigentümer
Aktien: 292.03 Mio. St.
f.h. Aktien: 287.36 Mio. St.
Insider Eigner: 1.6%
Instit. Eigner: 26.48%
>OCUGEN Peer Group

 
23.06.25 - 20:54
Ocugen (OCGN) Shares Slide Following Merger Agreement: What€s Going On? (Benzinga)
 
Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics. read more...
23.06.25 - 13:33
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases (GlobeNewswire EN)
 
PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq: OCGN) (Ocugen), a clinical-stage company developing regenerative cell therapies for orthopedic diseases, today jointly announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the development of OrthoCellix's NeoCart® technology for the treatment of knee articular cartilage defects and plans to initiate a U.S. Food and Drug Administration (FDA)-endorsed Phase 3 clinical trial for NeoCart®....
16.06.25 - 15:42
Ocugen gets FDA clearance to begin mid-stage study of OCU410ST (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.06.25 - 13:06
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease (GlobeNewswire EN)
 
MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3....
11.06.25 - 13:36
Ocugen To Present at BIO International Convention 2025 (GlobeNewswire EN)
 
MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BIO International Convention at the Boston Convention & Exhibition Center from June 16-19, 2025....
05.06.25 - 15:36
Ocugen signs license deal with Korean company for gene therapy (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.06.25 - 13:03
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea (GlobeNewswire EN)
 
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a well-established leader in the pharmaceutical and healthcare sector in Korea, for exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP)....
27.05.25 - 15:48
Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.05.25 - 13:03
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease (GlobeNewswire EN)
 
MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) has granted Rare Pediatric Disease Designation (RPDD) for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previously, OCU410ST received Orphan Drug designations for the treatment of ABCA4-associated retinopathies from the FDA and European Medicines Agency....
09.05.25 - 14:09
Ocugen GAAP EPS of -$0.05 beats by $0.01, revenue of $1.48M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.05.25 - 14:03
Ocugen Provides Business Update with First Quarter 2025 Financial Results (GlobeNewswire EN)
 
Conference Call and Webcast Today at 8:30 a.m. ET...
08.05.25 - 20:48
Ocugen Q1 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.05.25 - 14:03
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results (GlobeNewswire EN)
 
MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025....
29.04.25 - 13:33
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress (GlobeNewswire EN)
 
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah from May 4-8, 2025, and Retina World Congress at the Marriott Harbor Beach Resort in Ft. Lauderdale, Florida from May 8-11, 2025....
08.04.25 - 14:06
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med (GlobeNewswire EN)
 
MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy....
18.03.25 - 13:06
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema (GlobeNewswire EN)
 
MALVERN, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU200 clinical trial recently convened and reviewed safety data following dosing of the first cohort in the dose-escalation portion of the Phase 1 study and approved continuation of dosing in the second cohort. OCU200 is a novel fusion protein consisting of two human proteins, tumstatin and transferrin, with the potential to treat diabetic macular edema (DME)....
05.03.25 - 19:24
Ocugen (OCGN) Q4 2024 Earnings Call Transcript (Fool)
 
OCGN earnings call for the period ending December 31, 2024....
05.03.25 - 13:15
Ocugen GAAP EPS of -$0.05 in-line, revenue of $0.76M beats by $0.46M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.03.25 - 13:06
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire EN)
 
Conference Call and Webcast Today at 8:30 a.m. ET Conference Call and Webcast Today at 8:30 a.m. ET...
04.03.25 - 16:36
Ocugen Q4 2024 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Für mich ist Stille im Wesentlichen das Aufgeben jeglicher Absicht. - John Cage
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!